Rituximab in PR3-ANCA positive patients with moderately to severely active ulcerative colitis: a multicenter real-world pilot study
In moderately to severely active UC patients with PR3-ANCA+, RTX showed better effectiveness than infliximab (IFX), with a similar safety profile.
Authors
- Liangru Zhu (ORCID: https://orcid.org/0000-0002-7372-294X)
- Huan Wang (ORCID: https://orcid.org/0000-0002-7010-3086)
- Ying Li (ORCID: https://orcid.org/0000-0002-2693-6056)
- Fang Liu (ORCID: https://orcid.org/0000-0001-8140-6800)
- Yidong Chen (ORCID: https://orcid.org/0000-0002-7866-7628)
- Jiamin Li (ORCID: https://orcid.org/0000-0002-5352-2828)
- Xiaoyu Fu
- Junrong Li (ORCID: https://orcid.org/0000-0002-8292-990X)
- Yiyu Cheng (ORCID: https://orcid.org/0000-0003-1423-162X)
- Xiao‐Peng Zhang (ORCID: https://orcid.org/0000-0001-8170-1236)
- Qi Yu
Institutions
- Shihezi University (CN)
- Union Hospital (HK)
- First Affiliated Hospital of Shihezi University Medical College (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fphar.2025.1621795
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province